Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research
Open Access
- 27 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (9) , 4348-4354
Abstract
Background: Breast cancer is one of the most frequent causes of cancer death in women. The application of immunotoxins to target overexpressed biomarkers on the surface of cancer cells and delivery of the toxin molecules into these cells has attracted too much attention during the last decade. Objectives: This study was conducted to investigate the possible in-vitro cytotoxic and apoptotic activity of previously designed recombinant immunotoxin compromising anti-HER2 single-chain variable fragment (scFv) and alpha-luffin protein in human epidermal growth factor receptor type 2 (HER2)-positive and HER2-negative breast cancer cell lines. Materials and methods: The previously designed recombinant immunotoxin and alpha-luffin protein were expressed in E. coli host cells and purified using Ni-affinity chromatography. The cytotoxicity of the proteins was tested through MTT and apoptosis studies on HER2-positive and HER2-negative breast cancer cell lines. Results: Treatment of SKBR3 and MDA-MB-468 cells with the immunotoxin caused differential cytotoxicity and apoptotic events. Flow cytometry analysis indicated that the immunotoxin could arrest SKBR3 cells at the G0/G1 phase and induce apoptosis and cell death which were not observed in HER2-negative MDA-MB-468 cells. Annexin V/PI staining revealed late apoptotic events in SKBR3 cells treated with the immunotoxin which was different from the early apoptosis induced by the alpha-luffin protein alone. Conclusions: This immunotoxin could be a promising tool in developing new targeted therapeutic agents against HER2-positive cancer cells. Animal experiments are needed before making firmed conclusions.Keywords
This publication has 40 references indexed in Scilit:
- Momordica Charantia Lectin, a Type II Ribosome Inactivating Protein, Exhibits Antitumor Activity toward Human Nasopharyngeal Carcinoma Cells In Vitro and In VivoCancer Prevention Research, 2012
- Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer TherapyToxins, 2011
- PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potentialBiotechnology Letters, 2010
- A novel recombinant immunotoxin with the smallest ribosome‐inactivating protein Luffin P1: T‐cell cytotoxicity and prolongation of allograft survivalJournal of Cellular and Molecular Medicine, 2010
- Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and SurvivalClinical Medicine & Research, 2009
- Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricinThe International Journal of Biochemistry & Cell Biology, 2009
- Chemical Modifications of Momordin-a and Luffin-a, Ribosome-Inactivating Proteins from the Seeds ofMomordica charantiaandLuffa cylindrica: Involvement of His140, Tyr165, and Lys231 in the Protein-Synthesis Inhibitory ActivityBioscience, Biotechnology, and Biochemistry, 1998
- Receptor Protein-Tyrosine Kinases and Their Signal Transduction PathwaysAnnual Review of Cell Biology, 1994
- Isolation and Characterization of Two Momordins, Ribosome-Inactivating Proteins from the Seeds of Bitter Gourd (Momordica charantia)Bioscience, Biotechnology, and Biochemistry, 1992
- Protein‐synthesis inhibitory protein from seeds of Luffa cylindria roemFEBS Letters, 1983